ストックスクリーナーアプリを入手
14.93
1.65%
-0.25
アフターアワーズ：
15.12
0.19
+1.27%
前日終値:
$15.18
開ける：
$15.04
24時間の取引高:
30,178
Relative Volume:
0.32
時価総額：
$150.92M
収益：
$88.50M
当期純損益:
$-35.27M
株価収益率:
-4.5306
EPS:
-3.2954
ネットキャッシュフロー:
$-23.70M
1週間 パフォーマンス:
+5.36%
1か月 パフォーマンス:
+28.93%
6か月 パフォーマンス:
+118.59%
1年 パフォーマンス:
+109.75%
1日の値動き範囲:
$14.72
$15.43
1週間の範囲:
$13.58
$15.44
52週間の値動き範囲:
$5.00
$20.21
Biodesix Inc Stock (BDSX) Company Profile
Compare BDSX vs TMO, DHR, IDXX, WAT, A
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BDSX
Biodesix Inc
|
14.93 | 153.45M | 88.50M | -35.27M | -23.70M | -3.2954 |
TMO
Thermo Fisher Scientific Inc
|
448.28 | 167.00B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
172.00 | 122.68B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
559.37 | 43.63B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
342.37 | 33.48B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
114.96 | 32.44B | 7.07B | 1.29B | 993.00M | 4.5355 |
Biodesix Inc Stock (BDSX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-27 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2025-05-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-09-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-07-26 | 開始されました | Craig Hallum | Buy |
| 2024-05-13 | 開始されました | TD Cowen | Buy |
| 2024-05-03 | 開始されました | Lake Street | Buy |
| 2021-11-17 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-23 | 開始されました | BTIG Research | Buy |
| 2020-11-23 | 開始されました | Canaccord Genuity | Buy |
| 2020-11-23 | 開始されました | Morgan Stanley | Overweight |
| 2020-11-23 | 開始されました | William Blair | Outperform |
すべてを表示
Biodesix Inc (BDSX) 最新ニュース
Wall Street Analysts Believe Biodesix (BDSX) Could Rally 104.29%: Here's is How to Trade - Zacks Investment Research
Canaccord Lifts PT on Biodesix (BDSX) on Raised Revenue Assumptions - Insider Monkey
Biodesix (NASDAQ: BDSX) registers 375,000 shares for Perceptive resale - Stock Titan
Biodesix meets investors in Minneapolis, Chicago and Dana Point - Stock Titan
Biodesix to Participate in Upcoming Investor Conferences - Caledonian Record
Biodesix shareholders elect directors and approve executive compensation By Investing.com - Investing.com Australia
Biodesix shareholders elect directors and approve executive compensation - Investing.com
Biodesix Shareholders Approve Directors and Governance Measures - TipRanks
Biodesix (NASDAQ: BDSX) holders back directors, pay and KPMG auditor - Stock Titan
BDSX Stock Price, Quote & Chart | BIODESIX INC (NASDAQ:BDSX) - ChartMill
Perceptive entities disclose 4.6% holding in Biodesix (NASDAQ: BDSX) - Stock Titan
Biodesix BDSX Q2 2025 Earnings Call Transcript - AOL.com
Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy - The Manila Times
Blood test for lung nodules gets real-world spotlight at ATS 2026 - Stock Titan
Biodesix to present new real-world data on Nodify Lung testing at ATS 2026, highlighting clinical and economic benefits. - Pluang
Does Biodesix (BDSX) have the potential to rally 103.33% as Wall Street analysts expect? - MSN
Biodesix (NASDAQ: BDSX) holder Soleus reports 416,599 shares (4.1%) - Stock Titan
Biodesix Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Q3 2025 Biodesix Inc Earnings Call Transcript - GuruFocus
Number of shareholders of Biodesix, Inc. – NASDAQ:BDSX - TradingView
Does Biodesix (BDSX) Have the Potential to Rally 103.33% as Wall Street Analysts Expect? - Yahoo Finance
Biodesix Earnings Call Signals Strong Growth Momentum - The Globe and Mail
Biodesix Faces Mounting Reimbursement and Enforcement Risks as Evolving Payer Policies Threaten Revenue Stability - TipRanks
TD Cowen Maintains Biodesix(BDSX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
MSN Money - MSN
Canaccord Genuity Group Issues Positive Forecast for Biodesix (NASDAQ:BDSX) Stock Price - MarketBeat
Biodesix touts ‘clear path toward profitability’ - BizWest
William Blair Maintains Biodesix(BDSX.US) With Buy Rating - Moomoo
Lake Street Maintains Biodesix(BDSX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
CCORF Maintains Biodesix(BDSX.US) With Buy Rating, Raises Target Price to $22 - Moomoo
Biodesix Inc. 10-Q Q1 2026: Financial Statements, Risk Factors, and Management Analysis - Minichart
Biodesix stock price target raised to $22 by Canaccord on revenue growth - Investing.com
Biodesix, Inc. (NASDAQ:BDSX) Q1 2026 Earnings Call Transcript - Insider Monkey
Biodesix (BDSX) Q1 2026 Earnings Transcript - AOL.com
Biodesix, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Biodesix Q1 Earnings Call Highlights - MarketBeat
BDSX Financials: Income Statement, Balance Sheet & Cash Flow | BIODESIX INC - Stock Titan
BDSX: Q1 revenue up 42% year-over-year, with raised 2026 guidance and margin expansion - TradingView
Biodesix Q1 2026 Earnings Call: Complete Transcript - Benzinga
Earnings call transcript: Biodesix Q1 2026 shows revenue growth, stock steady - Investing.com
Biodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Biodesix Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Biodesix Inc (NASDAQ:BDSX) Q1 Results Smash Estimates, Shares Jump on Raised Guidance - ChartMill
Biodesix (NASDAQ:BDSX) Announces Earnings Results, Beats Estimates By $0.32 EPS - MarketBeat
Q1 2026 Biodesix Inc Earnings Call Transcript - GuruFocus
Biodesix Announces First Quarter 2026 Results and Highlights - The Manila Times
Biodesix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Biodesix Inc (BDSX) 財務データ
収益
当期純利益
現金流量
EPS
0.72%
0.29%
大文字化:
|
ボリューム (24 時間):